Moderna's Revenue Decline May Be Slowing, But Analyst Uncertainty Lingers Around Execution
Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.
Part 2.1: Price Behavior Around Earnings
Moderna typically reports earnings before the market opens, meaning Day 0 represents the first full trading session where investors react to results, while Day +1 captures follow-through momentum.
| Earnings Date | Day 0 Move | Day 0 Range | Day +1 Move | Day +1 Range |
|---|---|---|---|---|
| 2026-05-01 | -$0.57 (-1.24%) | $4.72 (10.27%) | +$1.93 (+4.25%) | $2.68 (5.90%) |
| 2026-02-13 | +$2.12 (+5.29%) | $3.60 (8.98%) | +$1.70 (+4.03%) | $3.10 (7.35%) |
| 2025-11-06 | +$0.77 (+3.27%) | $1.90 (8.06%) | +$0.21 (+0.86%) | $1.53 (6.29%) |
| 2025-08-01 | -$1.95 (-6.61%) | $1.32 (4.45%) | +$0.04 (+0.13%) | $1.42 (5.14%) |
| 2025-05-01 | -$1.51 (-5.29%) | $1.79 (6.27%) | +$0.58 (+2.15%) | $0.95 (3.51%) |
| 2025-02-14 | +$1.07 (+3.35%) | $4.66 (14.60%) | +$2.76 (+8.37%) | $4.94 (14.97%) |
| 2024-11-07 | -$1.53 (-2.95%) | $6.76 (13.04%) | -$3.45 (-6.86%) | $4.33 (8.61%) |
| 2024-08-01 | -$25.05 (-21.01%) | $9.30 (7.80%) | -$7.59 (-8.06%) | $7.25 (7.70%) |
| Avg Abs Move | 6.13% | 9.18% | 4.34% | 7.43% |
Historical price action around Moderna's earnings releases shows significant volatility, with the stock averaging an absolute move of 6.13% on Day 0 and 4.34% on Day +1. The Day 0 trading range averages 9.18%, while Day +1 sees an average range of 7.43%, indicating sustained volatility into the second session.
The most recent earnings release (May 1, 2026) saw a modest 1.24% decline on Day 0 with a 10.27% intraday range, followed by a 4.25% gain on Day +1. The February 2026 report triggered a 5.29% Day 0 gain and 4.03% Day +1 gain, both with substantial intraday ranges exceeding 7%. However, the August 2024 report stands out as an extreme outlier, with a devastating 21.01% Day 0 decline—likely reflecting a significant fundamental disappointment or guidance cut that skews the historical averages.
Excluding that outlier, the pattern suggests investors should expect Day 0 moves in the 3-6% range with potential for follow-through on Day +1, particularly if the company delivers another substantial earnings beat or provides encouraging pipeline updates.
Part 2.2: Options Market Expected Move
| Metric | Value |
|---|---|
| Expiration Date | 07/31/26 (DTE 1) |
| Expected Move | $3.76 (6.49%) |
| Expected Range | $54.16 to $61.68 |
| Implied Volatility | 189.29% |
The options market is pricing an expected move of 6.49% for this earnings release, which aligns closely with the 6.13% average absolute Day 0 move from recent history. This suggests options traders are anticipating typical volatility rather than an outsized reaction, despite the stock's history of significant earnings beats.
Part 3: What Analysts Are Saying
The analyst community maintains a cautious stance on Moderna, with a consensus rating of 2.96 (Hold) based on 23 analysts. The breakdown shows 2 Strong Buy ratings, 18 Hold ratings, 1 Moderate Sell, and 2 Strong Sell ratings—reflecting a predominantly neutral-to-skeptical view despite the company's recent operational improvements.
The average price target of $51.95 implies 10.3% downside from the current price of $57.92, with estimates ranging from a low of $25.00 to a high of $135.00. This wide dispersion reflects significant disagreement about the company's long-term value, with bears questioning the sustainability of revenue post-COVID and bulls betting on pipeline success.
Sentiment has improved over the past month, with one analyst upgrading from Strong Sell to Moderate Sell. However, the overall tone remains defensive, as the consensus target sitting below the current price suggests analysts believe the stock has run ahead of fundamentals. Recent target increases from Goldman Sachs (to $67) and Royal Bank of Canada (to $45) acknowledge improving near-term performance but stop short of bullish recommendations, maintaining neutral ratings that reflect wait-and-see positioning on the company's diversification efforts.
Part 4: Technical Picture
The Barchart Technical Opinion currently shows a 56% Buy signal, down from 64% last week and 100% last month, indicating deteriorating technical momentum heading into the earnings release. This weakening signal suggests the stock has lost some of its bullish conviction despite trading above key long-term moving averages.
Timeframe Analysis:
- Short-term (50% Buy): Neutral-to-slightly-bullish signal indicates near-term momentum has stalled after recent weakness
- Medium-term (50% Buy): Neutral reading suggests the stock is consolidating in the intermediate timeframe without clear directional bias
- Long-term (100% Buy): Strong buy signal reflects positive positioning in the longer-term trend, supported by the stock's position well above its 200-day moving average
Trend Characteristics: The combination of Average strength and Average direction suggests Moderna is in a neutral trend environment heading into earnings, lacking the strong momentum that would typically support a bullish breakout but also not showing signs of technical breakdown.
At $57.92, the stock trades above its 5-day ($55.58), 10-day ($57.40), 100-day ($54.74), and 200-day ($44.72) moving averages, but has fallen below its 20-day ($64.99) and 50-day ($58.22) averages.
| Period | Value | Period | Value |
|---|---|---|---|
| 5-Day MA | $55.58 | 50-Day MA | $58.22 |
| 10-Day MA | $57.40 | 100-Day MA | $54.74 |
| 20-Day MA | $64.99 | 200-Day MA | $44.72 |
The recent breakdown below the 20-day and 50-day moving averages after trading as high as $85.60 in the 52-week range signals a loss of near-term momentum. The stock's position above longer-term averages provides some technical support, but the weakening Barchart Opinion and proximity to the 50-day average at $58.22 suggests limited cushion if earnings disappoint. The technical setup is cautiously neutral—supportive enough that a strong beat could trigger a rally back toward the $65 level, but vulnerable to a test of the $54-55 support zone if results or guidance fall short of expectations.